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BACKGROUND: HDL-mediated cholesterol efflux capac-
ity (HDL-CEC) is a functional attribute that may have a
protective role in atherogenesis. However, the estimation
of HDL-CEC is based on in vitro cell assays that are
laborious and hamper large-scale phenotyping.
METHODS: Here, we present a cost-effective high-throughput
nuclear magnetic resonance (NMR) spectroscopy
method to estimate HDL-CEC directly from serum. We
applied the new method in a population-based study of
7603 individuals including 574 who developed inci-
dent coronary heart disease (CHD) during 15 years of
follow-up, making this the largest quantitative study
for HDL-CEC.
RESULTS: As estimated by NMR-spectroscopy, a 1-SD
higher HDL-CEC was associated with a lower risk of
incident CHD (hazards ratio, 0.86; 95%CI, 0.79–0.93,
adjusted for traditional risk factors and HDL-C). These
findings are consistent with published associations based
on in vitro cell assays.
CONCLUSIONS: These corroborative large-scale findings
provide further support for a potential protective role of
HDL-CEC in CHD and substantiate this new method
and its future applications.
© 2019 American Association for Clinical Chemistry
Circulating HDL particles mediate reverse cholesterol
transport by carrying excess cholesterol from the periph-
ery, such as the arterial wall, to the liver for excretion into
the bile. HDL cholesterol (HDL-C)14 is an established
epidemiological risk factor for cardiometabolic condi-
tions (1 ). However, the role of HDL-C remains unclear
because most HDL-C increasing therapies have, on the
whole, failed to prevent cardiovascular events (2 ), and
Mendelian randomization studies have given consistent
evidence that HDL-C is not causal in the development of
cardiovascular disease (CVD) (3 ). Although the recent
REVEAL (Randomized EValuation of the Effects of
Anacetrapib Through Lipid-modification) trial (4 ) of the
cholesteryl ester transfer protein inhibitor anacetrapib re-
sulted in a lower risk of major coronary events, rather
than providing evidence for a causal role of HDL-C,
these findings were entirely proportional to the reduction
in apolipoprotein B-containing lipoproteins (5, 6 ).
Therefore, the totality of evidence does not support
a causal role for HDL-C in coronary heart disease
(CHD). This has shifted the focus of HDL research from
circulating HDL-C concentrations to other aspects of
HDL, such as the functional attributes of HDL particles
(7, 8 ). Cholesterol efflux capacity of HDL (HDL-CEC),
which quantifies the ability of HDL particles to extract
cholesterol from lipid-laden cells, has emerged as the
most widely used metric for HDL function. HDL-CEC
reflects the combined action of various HDL particles via
multiple cellular pathways (9 ): intracellular cholesterol is
extracted by HDL via adenosine triphosphate (ATP)-
binding cassette transporters (ABCA1 and ABCG1),
scavenger receptor B1 (SR-B1), and simply by passive
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diffusion (9 ). There are multiple cellular efflux assays
available either to target specific pathways or their
combination (7, 10, 11 ). The most common assay to
analyze HDL-CEC uses cyclic adenosine monophos-
phate (cAMP)-treated J774 murine macrophages with
radiolabelled cholesterol (10, 12–14). HDL-CEC mea-
sured in cAMP-treated J774 cells incorporates all the
aforementioned pathways (12 ). A fluorescence-labeled
cholesterol method has also been used (11, 14 ). Despite
variation in the relative contributions from the different
efflux pathways, the correlation between HDL-CEC
quantified by these 2 assays is quite high (11, 15 ).
In recent years, several studies have investigated the
association of HDL-CEC with cardiovascular risk in in-
dividuals, with quantification of HDL-CEC mainly by
cAMP-treated J774 cells (10, 11, 14, 16 ). These studies
were recently summarized in a meta-analysis that
strengthened the evidence that HDL-CEC is inversely
associated with cardiovascular risk, with the association
being independent of HDL-C concentrations (14 ).
However, results from individual studies were inconsis-
tent (14 ) and large-scale evidence on HDL-CEC and
cardiovascular outcomes is currently limited to 2 studies,
one by Rohatgi et al. (11 ) and the other by Saleheen et al.
(10 ). Both of these studies identified inverse associations
between HDL-CEC and cardiovascular events indepen-
dent of established cardiovascular risk factors, including
HDL-C and/or apolipoprotein A1 (apoA1). Interest-
ingly, a recent study suggested HDL-CEC to be herita-
ble, independently of HDL-C (17 ). In epidemiological
studies, HDL-CEC is associated moderately with HDL-
related parameters, such as HDL-C (10, 11, 17 ), HDL
size (11, 17 ), and total HDL particle concentrations
(HDL-P) (11, 17 ), but weakly with clinical variables
[such as body mass index (BMI) and blood pressure]
(10, 11 ). Large-scale characterization of the associations
ofHDL-CECwithmultiple cardiometabolic risk factors,
as well as HDL subclasses, is currently lacking. The rela-
tive paucity of large-scale epidemiology is most likely
owing to the complexity and cost of cellular HDL-CEC
assays. Novel approaches are needed to facilitate such
measurements and enable large-scale investigations of the
epidemiological role, genetic architecture, and potential
causality of HDL-CEC.
To this end, we have developed a high-throughput,
cost-effective alternative approach to the estimation of
HDL-CEC through serum nuclear magnetic resonance
(NMR) spectroscopy. Recent advancements in experi-
mentation and automated molecular quantifications
have made applications of quantitative NMR in epide-
miology and genetics increasingly common in recent
years (18, 19 ). These advances have taken NMR-based
approaches into large-scale research beyond their well-
known role in detailed quantification of lipoprotein sub-
classes, particles, and lipids (18–20). We show here that
it is possible to estimate HDL-CEC from serum NMR
spectra and that quantification recapitulates the charac-
teristics of in vitro HDL-CEC in cAMP-treated J774
cells. This report presents the new high-throughput
methodology and confirmatory results regarding the as-
sociations of HDL-CEC and incident CHD in a large-
scale prospective epidemiological study.
Materials and Methods
An overview of the study is described in Fig. 1 in theData
Supplement that accompanies the online version of this
article at http://www.clinchem.org/content/vol65/issue8.
TRAINING DATA
Random blood samples were collected during 2016 from
the Finnish Red Cross blood service in accordance with
the ethical guidelines required by the Helsinki Declara-
tion. Serum was obtained by centrifugation at 1500g for
15 min at ambient temperature and stored at 80 °C.
HDL-CECwas measured using cAMP-treated J774 cells
within a year of sample collection (details of in vitro
HDL-CEC measurement are given in Methods in the
online Data Supplement and Table 1 in the online Data
Supplement). The same serum samples were also ana-
lyzed by protonNMR spectroscopy within the same time
frame. The complete training data set obtained comprised
199 individuals with the serum NMR spectra and the cor-
responding cellular in vitro HDL-CEC estimates. Bayesian
regressionmodelingwas applied to link theNMRspectra to
theHDL-CECestimates (21); the correspondence between
the NMR-based and the cellular in vitro HDL-CEC esti-
mates is shown in Fig. 2 in the online Data Supplement.
Characteristics of the individuals in the training data set are
given in Table 2 in the online Data Supplement.
NMR SPECTROSCOPY AND SAMPLE PREPARATION
A high-throughput NMR spectroscopy platform with an
optimized measurement protocol was used to provide
quantitative information on themultiplemolecular constit-
uents of serum. The experimental details have been previ-
ously published (22). The NMR spectroscopic details are
identical to the main quantitative NMR metabolomics
method (18, 19), and the overall spectral characteristics
have been detailed and discussed previously (18, 22). Lipo-
protein quantification and HDL-CEC modeling methods
are described in Methods in the online Data Supplement.
EPIDEMIOLOGICAL STUDY POPULATION AND STATISTICAL
ANALYSES
The FINRISK97 survey was carried out to monitor the
health of the Finnish population among persons of age
25–74 years at recruitment (23 ). The study was con-
ducted in 5 study areas across Finland, recruiting a total
of 8444 persons. The Ethics Committee of the National
Estimation of HDL-Mediated Cholesterol Efﬂux
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Public Health Institute, Helsinki, Finland, has approved
the study in accordance with the Declaration of Helsinki,
and written informed consent has been obtained from all
participants. Serum samples were collected in 1997 in the
semifasting state (median fasting time, 5 h; interquartile
range, 4–6 h) and stored at70°C. The NMR analyses
took place in 2012. Statistical analyses are described in
Methods in the online Data Supplement.
Results
HDL-CEC ESTIMATION VIA SERUM NMR SPECTROSCOPY
Using a Bayesian linear regression model, we established
a quantitative relationship between the NMR spectral
regions of lipoprotein resonances and in vitro measured
HDL-CEC. We found a good correspondence (R2 of
0.83; see Fig. 2 in the online Data Supplement) and low
mean bias (see Bland–Altman plot in Fig. 3 in the online
Data Supplement) betweenNMR-basedHDL-CEC and
in vitro HDL-CEC.
ASSOCIATION OF HDL-CEC WITH INCIDENT CHD AND
CVD EVENTS
Several studies have found inverse associations between
HDL-CEC and cardiovascular outcomes, although re-
sults are heterogeneous. We were interested to see
whether the analysis using NMR-quantified HDL-CEC
would replicate findings by prior studies based on in vitro
HDL-CEC assays.We analyzed the association of NMR-
based HDL-CEC with incident cardiovascular events in
a large-scale population-based FINRISK97 cohort (7290
individuals with 574 incident CHD events and 7231
individuals with 789 incident CVD events during 15
years of follow-up; see Methods in the online Data Sup-
Fig. 1. Kaplan–Meier cumulative incidence and HRs of CHD by quartiles of NMR-based HDL-CEC.
HRs were calculated by Cox proportional hazardmodels with the lowest quartile as the reference group.Model 1: Traditional risk factors [age,
sex, geographical region, diabetes, mean arterial blood pressure, blood pressure treatment, smoking, log BMI, total cholesterol, log TG
(triglycerides), lipid lowering treatment], HDL-C. Model 2: Model 1, apoA1, and HDL-P. †, Additional statistics for Log-rank test (chi-squared=
22.2; df = 3; 2-sided).
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plement). The Kaplan–Meier curves in Fig. 1 illustrate
the association of NMR-based HDL-CEC quartiles with
risk of incident CHD events during follow-up for the
individuals in the FINRISK97 cohort. The hazard ratio
(HR) between the top and bottom quartile of the NMR-
based HDL-CEC values was 0.63 (95% CI 0.50–0.80)
(Fig. 1). The event curves show a dose–response at the
median threshold, but the association is nonlinear
through the quartiles, as reflected also by the cubic spline
of the continuous HR across HDL-CEC values (see Fig.
4 in the online Data Supplement). Detailed analyses with
multiple adjustments are presented in Table 3 in the
online Data Supplement. A similar association was ob-
tained for the association of HDL-CEC with CVD (see
Fig. 5 in the online Data Supplement). HDL-CEC re-
mained associated with CHD andCVD events even after
adjustment for traditional risk factors and all otherHDL-
related measures, including HDL-C, apoA1, and total
HDL-P; top vs bottom quartile HR for CHD 0.74 (95%
CI, 0.57–0.95) (Fig. 1) andHR for CVD 0.79 (95%CI,
0.64–0.98; see Fig. 5 in the online Data Supplement).
The trend to an association for hard atherosclerotic
CVD, together with myocardial infarction (MI) and
stroke separately, was consistent with the association for
total CHD (see Table 4 in the online Data Supplement).
We also analyzed the association of HDL-CEC for inci-
dent CHD events across various clinical subgroups (see
Fig. 6 in the online Data Supplement) and detected no
subgroup interactions.
Previously Rohatgi et al. (11 ) examined MI and
CVD in 2416 individuals over a median follow-up of 9.4
years in a population-cohort with 30 and 172 endpoints,
respectively, and Saleheen et al. (10 ) used a prospective
nested case–control study with 1745 patients with inci-
dent CHD and 1749 control participants. We chose
these largest HDL-CEC endpoint studies as a reference.
Table 5 in the online Data Supplement presents compar-
isons for the associations of the in vitro measured HDL-
CEC in cAMP-treated J774 cells withMI andCVD (11 )
and CHD (10 ) outcomes with the current results for the
NMR-basedHDL-CEC estimates andCHD in the FIN-
RISK97 cohort. All the main associations based on the in
vitro estimates, including those with various adjust-
ments, were replicated with the NMR-based estimates
(see Methods in the online Data Supplement for statisti-
cal analyses). Consistent with the findings by Rohatgi et
al. (11 ) and Saleheen et al. (10 ) our independent large-
scale study also supports the inverse association of HDL-
CEC for cardiovascular outcomes. An additional consis-
tent feature in the prior studies together and in our data is
that the associations of HDL-CEC with vascular out-
comes are robust to multiple adjustments, including
HDL-C, apoA1, and total HDL particle concentration
(HDL-P).
Rohatgi et al. (11 ) also analyzed the improvement in
risk prediction after adding HDL-CEC with traditional
risk factors in prediction models. This resulted in small
improvements in all the risk-prediction indexes for the
primary endpoint (consisting of atherosclerotic CVD),
including changes in the c-statistic from 0.827–0.841
(P  0.02), the integrated discrimination improvement
index (IDI) of 0.02 (P 0.001), and the net reclassifica-
tion index (NRI) of 0.37 (95% CI, 0.18, 0.56). In our
analyses with well-calibrated models (see Fig. 7 in the
online Data Supplement), addition of HDL-CEC to tra-
ditional risk factors and HDL-C was also associated with
small improvements in CHD prediction with improve-
ments in the c-statistic [from 0.841 (95%CI, 0.829,
0.854) to 0.843 (95%CI, 0.830, 0.856); P  0.02 by
Student t-test for dependent samples: t.stat 1.20, df
7290, 1-sided], IDI of 0.005 (95%CI, 0.001, 0.015),
and continuous NRI of 0.21 (95%CI, 0.05, 0.28). Sim-
ilar improvements were observed for CVD prediction
with c-statistics [from 0.837 (95%CI, 0.825, 0.848) to
0.838 (95%CI, 0.826, 0.849); P 0.01 by Student t-test
for dependent samples: t.stat  2.29, df  7230,
1-sided], IDI of 0.004 (95%CI, 0.001, 0.010), and con-
tinuous NRI of 0.18 (95%CI, 0.04, 0.26). Hosmer–
Lemeshow statistics for model calibration with CVD
were 2 0.021, P 1, df 8 and 2 0.020, P 1,
df  8 for models with and without HDL-CEC,
respectively.
We also wanted to compare how the associations for
our FINRISK97 cohort using the NMR-based HDL-
CEC estimates compared with those from previous stud-
ies, as reported in a recent meta-analysis (14 ). Fig. 2
presents the association of HDL-CEC with cardiovascu-
lar risk in this study with comparable data from themeta-
analysis (14 ). The results in the FINRISK97 study were
remarkably similar to the summary estimates of themeta-
analysis. For example, the risk ratio (RR) estimate for the
highest vs lowest quartile of HDL-CEC was 0.69
(95%CI: 0.54, 0.87; Fig. 1) in the FINRISK97 cohort,
consistent with the meta-analyzed RR estimate of 0.58
(0.39, 0.86) (14 ). Similarly, the per 1-SD higher HDL-
CEC RR estimate of 0.86 (0.79, 0.93; see Table 3 in the
online Data Supplement) in the FINRISK97 cohort was
nearly identical to the summarymeta-analysis RR of 0.87
(0.73, 1.04) (14 ). For both of these, there was no evi-
dence of heterogeneity between the current HDL-CEC
estimates and the pooled estimates from the meta-
analysis (P value 0.46 and 0.91 for highest vs lowest and
per-1-SD higher, respectively).
CORRELATIONS OF HDL-CEC WITH VARIOUS
ANTHROPOMETRIC, LIPOPROTEIN, AND CLINICAL VARIABLES
The cross-sectional correlations of NMR-based HDL-
CEC estimates with various traits in the FINRISK97
cohort are presented in Fig. 3 (exact correlation coeffi-
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cients are given in Table 6 in the online Data Supple-
ment) together with the corresponding values from Ro-
hatgi et al. (11 ) and Saleheen et al. (10 ). In addition,
Table 7 in the online Data Supplement describes the
various traits according to HDL-CEC quartiles. Analo-
gous to the previous studies, we identified positive corre-
lations of HDL-CEC with, for example, HDL-C, HDL
particle size, age, blood pressure, alcohol consumption,
and female sex. Negative correlations of HDL-CECwere
identified for apolipoprotein B, triglycerides, and mea-
sures of adiposity. The magnitudes of these correlations
were weak, which correspond with the findings reported
by Saleheen et al. (10 ). Unlike Saleheen, we did not find
a negative association between diabetes and HDL-CEC.
The correlations of HDL-CEC with HDL-C and HDL
particle size were even weaker in Rohatgi et al. (11 ).
Although HDL-CEC was positively correlated with
HDL-C and other HDL-related measures, the highest
correlation of HDL-CEC with HDL-C across these 3
studies was 0.4 (see Table 6 in the online Data Supple-
ment), supporting the view that HDL-CEC andHDL-C
contain largely independent information on HDL
metabolism.
ASSOCIATION OF HDL-CEC WITH HDL SUBCLASSES
Serum NMR spectroscopy enables the extensive quanti-
fication of lipoprotein subclasses, including particle con-
centrations for 4 HDL subclasses (18, 19 ). These data
Fig. 2. Associations of HDL-CEC with cardiovascular risk in the FINRISK97 (NMR-based) compared to previous studies (in vitro
cellular assays).
Previous studies, RR, and their meta-analyzed results were taken from a recent meta-analysis (14 ) investigating the association of HDL-CEC
with cardiovascular outcomes. Highest vs lowest denote the RR for CV events comparing the highest to the lowest HDL-CEC quantiles deﬁned
in each study. RR from the current FINRISK97 cohort was adjusted for age, sex, geographical region, diabetes, mean arterial blood pressure,
blood pressure treatment, smoking, log BMI, total cholesterol, log TG (triglycerides), lipid lowering treatment and HDL-C. Highest vs lowest
refers to top vs bottomquartile. There was no evidence of heterogeneity between the current study estimate and the pooled estimate from the
meta-analysis by Cochran’s Q test, 2-sided (P= 0.46; Q = 0.54; df = 1) and (P= 0.91; Q = 0.01; df = 1) for highest vs lowest and per-1-SD
higher, respectively.
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were not available in prior studies including Rohatgi et al.
(11 ) or Saleheen et al. (10 ). Fig. 4 shows correlations
between the particle concentrations of 4 HDL subclasses
(extra-large, large, medium, and small) and the HDL-
CEC, HDL-C, apoA1, and total HDL-P in FINRISK97
(NMR HDL-CEC) and training data (in vitro HDL-
CEC). Corresponding correlations stratified by sex are
presented in Fig. 8 in the online Data Supplement.
HDL-CEC correlated strongly with larger HDL subspe-
cies and the associations between HDL subclass particle
concentrations, as well as with other key HDL-related
measures, were coherent between the independent data
sets. This consistency of association is reassuring because
HDL-CEC has been reported to have quite variable as-
sociations with HDL-C in different cohorts: the correla-
tion between HDL-CEC and HDL-C was 0.4 in the
EPIC (European Prospective Investigation of Cancer)-
Norfolk study (10 ), 0.62 in the Genetic Regulation
of Arterial Pressure of Humans in the Community
(GRAPHIC) cohort (17 ), and 0.39 in the Justification
for the Use of Statins in Prevention: An Intervention
Trial Evaluating Rosuvastatin (JUPITER) trial data
(13 ). More detailed association analysis between the
NMR-based HDL-CEC estimates and HDL subclass
lipids is shown in Fig. 9 in the online Data Supplement.
The distribution of HDL-CEC values in the
FINRISK97 cohort is shown in Fig. 10 in the online
Data Supplement and Spearman correlations between
the NMR spectral profile and various key HDL-related
measures in the training data set are illustrated in Fig. 11
in the online Data Supplement.
Discussion
We developed a high-throughput method to estimate
HDL-CEC directly from serum samples using NMR
spectroscopy. The method is based on HDL-CEC esti-
mates from in vitro measurements in cAMP-treated J774
cells, the most common technique to analyze HDL-CEC
in cardiometabolic research. The NMR-based HDL-
CEC estimates appear to capture the same key aspects as
the in vitro HDL-CEC with respect to associations with
various anthropometric, lipoprotein, and clinical vari-
ables as well as, importantly, with cardiovascular out-
comes. We applied the new NMR-based method to esti-
mate HDL-CEC in a large-scale epidemiological study,
the FINRISK97 cohort of approximately 7200 individ-
uals, among whom 574 CHD and 789 CVD incident
events occurred during 15 years of follow-up. This is
currently the largest epidemiological study of HDL-
CEC, the results of which also show independent inverse
associations of HDL-CEC with risk of CHD and CVD
lending support to a potential atheroprotective role of
HDL function.
The associations of NMR-based HDL-CEC with
risk of cardiovascular outcomes were in keeping with
summary estimates of a recent meta-analysis investigat-
ing the associations of cellular in vitro HDL-CEC esti-
mates with cardiovascular outcomes (14 ). A key finding
with the NMR-based HDL-CEC corroborating the ear-
lier findings with the cellular in vitro HDL-CEC in the
existing largest outcome studies (10, 11 ) was its associa-
tion withCHDbeing independent of otherHDL-related
measures, including HDL-C, apoA1, and HDL-P.
Therefore, the NMR-based HDL-CEC estimates reca-
pitulate the characteristics of cellular in vitro HDL-CEC
estimates and account for independent information on
CHD risk not captured by other HDL-related measures.
Cardiovascular risk prediction is rarely improved by
new biomarkers (24 ). Currently, the ability of HDL-
CEC to improve CVD risk prediction beyond traditional
Fig. 3. Associations of HDL-CEC with clinical and lipid
parameters.
In Rohatgi et al. (11 ) data are Spearman correlation coefﬁcients
and in Saleheen et al. (10 ) data are Pearson correlation coefﬁ-
cients adjusted for age and sex. In the FINRISK97 data are Spear-
man correlation coefﬁcients adjusted for age and sex; n = 7370
(exact correlation coefﬁcients and details in Table 6 in the online
Data Supplement). Dashdenotes that a correlation coefﬁcientwas
not available. a association for female sex. ***P < 0.001, **P <
0.01, *P< 0.05.
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risk factors has been investigated in 2 studies, both de-
scribing moderate increases in NRI: 38% (16 ) and 22%
(11 ), but relatively small increases in c-statistics. Accord-
ingly, we found an increase in NRI of 21% and small
increases in the c-statistics. A small increase in c-statistic is
expected, because this metric is insensitive inmodel com-
parisons when good predictors are already present in the
reference model (25 ).
HDL-CEC is a functional measure related to mul-
tiple characteristics of HDL particles, and therefore,
some level of correlation with other HDL-related mea-
sures would be expected. In the FINRISK97 cohort, rel-
atively weak correlations were observed, with the largest
being between the NMR-based HDL-CEC estimate and
mean HDL-particle size (correlation coefficient, 0.31).
In Saleheen et al. (10 ), the highest correlation was 0.4
between the cellular in vitro HDL-CEC estimate and
HDL-C. In the GRAPHIC cohort with HDL-CEC data
in 1988 individuals, a correlation of 0.62 between
HDL-C and HDL-CEC was found (17 ), and in the
JUPITER trial data, the highest correlation was 0.48 be-
tween HDL-CEC and apoA1 (13 ). Together with the
independent associations of HDL-CEC with the risk of
vascular disease, this points toward HDL-CEC contain-
ing independent information on HDL metabolism and
reverse cholesterol transport.
The present study is the first large-scale study inves-
tigating the association of HDL-CEC with HDL sub-
class measures. The HDL-CEC estimates associated with
very large and large, but not with medium and small,
HDL subclass particle concentrations. These findings
match those of previous small-scale studies using cAMP-
treated J774 cells (26, 27 ), and the predominance of the
associations with larger HDL particles is most likely due
to these particles having a larger receiving area for the
diffusing cholesterol molecules and thereby more effec-
tive mediation of diffusion than smaller particles (9 ).
This is particularly relevant here because diffusion is
thought to be the dominating mechanism for the choles-
terol efflux in radioactive cholesterol-labeled cAMP-
treated J774 cells (28 ) (see Methods in the online Data
Supplement). Diffusion is the main efflux mechanism in
cholesterol normal (nonloaded) cells (28, 29 ), indicating
that it has a role in maintaining cholesterol homeostasis
in cells at basal conditions, whereas macrophages with
cholesterol-loaded states, also known as foam cells,
have increased expression of ABC-transporters and en-
hanced cholesterol efflux through these pathways and
decreased contribution of aqueous diffusion-driven path-
way (28, 29 ). Currently, we do not know which path-
ways are most important in relation to CVD risk (30 ).
The new cost-effective NMR-based method pre-
sented here to estimate HDL-CEC directly from serum
samples is designed to correspond to the most common
assay to analyze HDL-CEC, i.e., using cAMP-treated
J774 murine macrophages with radiolabeled cholesterol
(10, 12–14). This latter methodology was used by Sale-
heen et al. (10 ), a large-scale outcome studywe compared
our current results with. The excellent correspondence of
our findings (using the NMR-based HDL-CEC esti-
mates) to those by Saleheen et al. (10 ) (using cAMP-
treated J774 murine macrophages) serves to corroborate
Fig. 4. Associations ofHDL-CEC and relatedmeasureswithHDL subclass particle concentrations in the FINRISK97 cohort (n=7597)
and in the training data (n = 198).
The FINRISK97 data are NMR-based HDL-CEC estimates and the training data are from in vitro HDL-CEC measurements. Data are Spearman
correlation coefﬁcients (95% CI) adjusted for age and sex. Filled symbols refer to P<0.007 and closed symbols to P≥0.007. HDL subclasses
were measured by NMR spectroscopy and are deﬁned by particle size as follows: XL-HDL, very large (average particle diameter 14.3 nm);
L-HDL, large (12.1 nm); M-HDL, medium (10.9 nm); S-HDL, small HDL (8.7 nm) (19 ). P value was adjusted for multiple testing by using
principal component analysis (see Methods in the online Data Supplement). HDL-P; total HDL particle concentration (a sum of the individual
HDL subclass particle concentrations).
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our approach and is in part expected, given that our
NMR assay was developed from the similar in vitro assay.
In contrast, the other large-scale outcome study by Ro-
hatgi et al. (11 ) applied a less common, fluorescence-
labeled [boron-dipyrromethene (BODIPY)] cholesterol
method in a similar cell model (11, 15 ). The correlation
between HDL-CEC estimates from these 2 cellular in
vitro assays is modest (11, 15 ), and it is therefore ex-
pected that the NMR-based HDL-CEC results in the
FINRISK97 cohort would also match with the results by
Rohatgi et al. (11 ) at some extent. However, the main
difference between radiolabeled and BODIPY-labeled
cholesterol efflux assays is that BODIBY-method favors
cholesterol efflux though ABCA1-transporter (15 ) that
mediates efflux to small HDL and lipid-poor pre- par-
ticles (31, 32 ), whereas radiolabeled cholesterol assay as-
sociates with large HDL particles (26, 27 ) due to move-
ment of radiolabeled cholesterol through all pathways
present in cAMP-treated J774 cells, diffusion having the
main contributing pathway. Thus, NMR-based HDL-
CEC is a proxy for radiolabeled cholesterol efflux assay
performed in cAMP-treated J774 cells and it may not
represent other efflux models. Despite that, our data are
also consistent with the pooled estimate of a recent meta-
analysis that summarizes the associations of in vitro
HDL-CEC estimates with cardiovascular outcomes (14),
which serves to further corroborate our NMR-quantified
HDL-CEC.
Although estimated HDL-CEC values seem to reca-
pitulate the key characteristics of in vitro HDL-CEC,
applications of this method to diverse populations, i.e.,
ethnic subgroups, individuals with extreme lipid values
or distinct disease states, should be interpreted with care.
Multiple recent drug trials have indicated that in-
creasing circulatingHDL-C concentrations does not lead
to a reduction in CVD (5 ). Mendelian randomization
studies also fail to support HDL-C having a causal role in
CVD (3 ). We should therefore remain skeptical about
the potential causality of HDL-CEC. Nevertheless, the
new cost-effective NMR-based method to estimate
HDL-CEC could be advantageous in widening the re-
search of cholesterol efflux to large population-based co-
horts and drug trials and to expedite appropriately pow-
ered studies in relation to multiple cardiovascular and
metabolic outcomes. Large-scale cohorts with HDL-
CEC estimates are needed to investigate and replicate the
associations of HDL-CEC with clinical outcomes and,
more importantly, to study the genetic determinants of
cholesterol efflux to perform Mendelian randomization
analyses for potential causality. We propose the new
NMR-basedmethod as a pragmatic alternative for HDL-
CEC estimates from in vitro measurements in cAMP-
treated J774 cells, particularly in large-scale epidemiol-
ogy and genetics. This method appears to have great
potential to lower the experimental costs related toHDL-
CEC measurements and concomitantly speed up collec-
tion of the extensive epidemiological evidence base
necessary to ascertain whether this functional HDL
phenotype is causal for vascular disease and, thus,
whether it provides an opportunity for translational
applications.
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